Search Results

You are looking at 31 - 40 of 480 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy

Justine Lequesne, Florence Joly, Julien Peron, Isabelle Ray-Coquard, Anne-Claire Hardy-Bessard, Frédéric Selle, Dominique Berton, Philippe Follana, Michel Fabbro, Alain Lortholary, Eric Pujade-Lauraine, Sophie Lefèvre-Arbogast, and Elodie Coquan

alone (CH arm: n=182) or with bevacizumab (BEV + CH arm: n=179). 11 Chemotherapy included paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan. Adding bevacizumab to chemotherapy significantly improved PFS, with a median PFS of 6.7 months (95

Full access

Avastin, ODAC, and the FDA: Are We Drafting the Right Players?

Harold J. Burstein

provide confirmatory evidence supporting the original ECOG 2100 study that had led to accelerated approval of bevacizumab in combination with paclitaxel for advanced breast cancer. The FDA will decide in September whether to withdraw the label for the

Full access

Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study

John H. Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F. Siadak, Maria Corinna Palanca-Wessels, Junhua Yu, Nicole Zhang, Carin R. Espenschied, Kathryn Lang, and Tanios S. Bekaii-Saab

follows: chemotherapy; anti-EGFR therapy ± chemotherapy; anti-VEGF therapy ± chemotherapy; HER2-directed therapy; tipiracil + trifluridine; regorafenib; and non–NCCN-recommended therapies (which included paclitaxel, carboplatin, cisplatin, gemcitabine

Full access

Practice-Changing Interventions in the Systemic Management of Breast Cancer

Presented by: William J. Gradishar

are given earlier in the course of metastatic disease rather than later, he added. Less frequently, microsatellite instability–high (MSI-H) status can also be exploited with the anti–PD-L1 agent atezolizumab + nab-paclitaxel. The rate NTRK fusions

Full access

Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management

Zhi Ven Fong and Cristina R. Ferrone

horizon for patients with metastatic PDAC significantly changed with the multiagent chemotherapy regimens fluorouracil/folinic acid/irinotecan/oxaliplatin (FOLFIRINOX) 4 and gemcitabine/nab-paclitaxel, 5 respectively. Median survival for patients with

Full access

Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

A. Dimitrios Colevas

SCCHN. 9 - 15 The most robustly studied agents are cisplatin, carboplatin, methotrexate, 5-fluorouracil (5-FU), ifosfamide, paclitaxel, and docetaxel ( Table 1 ). Response rates typically range from 10% to 30%, with some outlier reports of higher

Full access

Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer

Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle

combination chemotherapy ( Figure 2A ), which was predominantly with paclitaxel. By contrast, 86% of patients in the cisplatin cohort received cisplatin monotherapy ( Figure 2B ). H&N CSM was higher for single-agent carboplatin than for multiagent chemotherapy

Full access

Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary

Arantzazu Barquín García, Sara Palacios-Zambrano, Felipe Lozano Alarcón, Beatriz Paumard-Hernández, Miguel Quiralte Pulido, Paloma Navarro, Laura Rodríguez, Isabel Salas Villar, and Jesús García-Donas

. With these results, breast and urothelial carcinoma were excluded. After the patient was diagnosed with a stage IV tumor of unknown primary, first-line chemotherapy treatment was started with carboplatin at area under the curve 5 and paclitaxel at 175

Full access

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma

Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary

regimens, including gemcitabine plus nab-paclitaxel and FOLFIRINOX (5-fluorouracil, folinic acid, oxaliplatin, and irinotecan), have limited efficacy, with an incremental survival benefit of only a few months in unselected patients. However, significant

Full access

SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data

Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven

: Fluoropyrimidine, platinum, and irinotecan (eg, FOLFIRINOX [5-FU/leucovorin/oxaliplatin/irinotecan]) Regimens with gemcitabine and nab-paclitaxel Gemcitabine monotherapy Other regimens Predictor Preselection Predictors were selected based on